Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cue Biopharma reports robust clinical data and strategic partnerships

Cue Biopharma's Q4 2022 Earnings Call highlighted strong clinical data, strategic partnerships, and upcoming milestones that position the company for growth and innovation in the biopharmaceutical sector.
While facing challenges in determining optimal registration paths and patient stratification, Cue Biopharma remains focused on leveraging opportunities through partnerships, therapeutic breakthroughs, and financial stability.
With a clear focus on advancing their pipeline, Cue Biopharma aims to drive therapeutic advancements, expand their portfolio, and establish themselves as a key player in oncology treatments.

Cue Biopharma reports strong Q2 performance and eyes transformative 2024

Cue Biopharma's Q2 2023 performance showcased revenue growth, strong cash position, and promising clinical data from trials, underlining the company's commitment to precision immunotherapy in cancer treatment.
The company's strengths in harnessing natural immune signals, achieving significant antitumor activity, and exploring rational combinations position Cue Biopharma for transformative advancements.
Challenges in decision-making, dose determination, and regulatory pathways must be navigated, but opportunities in FDA resolutions, strategic decisions, and milestone achievements abound.
With a focus on data interpretation, partnerships, and transformative therapies, Cue Biopharma is poised for an exciting and impactful 2024 with multiple milestones and growth prospects.

Cue Biopharma reports positive trial outcomes and explores strategic partnerships

Cue Biopharma's Q3 showcased strong clinical progress and financial stability.
The company's Immuno-STAT platform trials displayed promising results.
Challenges include regulatory pathways and trial expansion plans.
Opportunities lie in strategic partnerships and exploring new treatment combinations.

Cue Biopharma reports solid financials and advances in immunotherapy

Cue Biopharma's financials show steady revenue growth and prudent expense management, ensuring operational funding into 2025.
The company's strengths lie in its focused approach to developing immunotherapeutic biologics and positive trial updates in oncology and autoimmune diseases.
Challenges include strategic decision-making on partnerships, trial design, and managing trial outcome expectations based on industry data.
Opportunities exist in strategic partnerships, advancements in oncology programs, and upcoming data presentations offering insights for stakeholders.

Cue Biopharma advances autoimmune programs and partnerships for treatment innovation

Cue Biopharma's focus on autoimmune programs and strategic partnerships reflects a commitment to redefining treatment standards for cancer and autoimmune diseases. Progress with key programs and the Immuno-STAT platform demonstrates potential for targeted therapies with improved efficacy and safety. Overcoming challenges in market conditions and regulatory landscapes while seizing opportunities in program advancements and partnerships will be critical for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors?

Are You Looking for a Top Momentum Pick? Why Cue Biopharma, Inc.

ACADIA Pharma

Compugen

Epizyme

uniQure

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

5 Biotech Stocks That Have More Than Doubled This Year

Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy

As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).

Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?

Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock

CAMBRIDGE, Mass., Oct.  15, 2019  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Houston Oncology Summit at the University of Texas MD Anderson Cancer Center on Thursday, October 17, 2019 at 10:40 a.m. CT in Houston, Texas.

Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center

Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development

Cue Biopharma Announces Changes to its Board of Directors

CAMBRIDGE, Mass., Oct.  09, 2019  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it is scheduled to present at the following scientific conferences in October:

Cue Biopharma to Present at Upcoming October 2019 Scientific Conferences

Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology

Cue Biopharma Promotes Dr. Anish Suri to President and CSO

CAMBRIDGE, Mass., Oct.  02, 2019  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Cantor 2019 Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York City.

Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference

CAMBRIDGE, Mass., Sept.  30, 2019  (GLOBE NEWSWIRE) --  Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that on September 23, 2019 it dosed the first patient in a Phase 1 clinical trial of CUE-101 at  Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri  for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Enabled by the company’s proprietary Immuno-STAT™ (Selective Targeting and Alternation of T cells) platform, CUE-101 is the company’s lead biologic drug candidate from the IL-2 based CUE-100 series, designed to directly engage and activate T cells in the body to target HPV-driven cancers.

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

News for Cue Biopharma Stock (CUE)